LeMaitre Q2 2026 Financial Results

LeMaitre Vascular delivered double-digit growth and record profitability in Q2 2026.

What the company is saying

LeMaitre Vascular, Inc. frames its Q2 2026 update as a demonstration of strong, broad-based growth and operational execution. The announcement highlights a 10% year-over-year sales increase, with organic growth matching the headline figure, and emphasizes record results across multiple product lines and geographies. Management underscores margin expansion, with gross margin up 210 basis points to 72.1% and operating margin reaching 29%. Capital allocation is positioned as shareholder-friendly, with a $0.25 per share quarterly dividend and a $100 million share repurchase authorization. The company presents forward guidance for Q3, Q4, and full-year 2026, projecting continued double-digit growth and stable margins. The tone is confident and data-driven, with George LeMaitre (Chairman/CEO) and Gregory Manker (Director of Business Development and Investor Relations) named as key figures, but the narrative remains focused on realised results rather than personalities.

What the data suggests

The reported numbers confirm a strong quarter: Q2 2026 sales reached $70.4 million, up 10% year-over-year, with organic growth also at 10%. Gross margin improved to 72.1%, a 210 basis point increase, and operating income rose 26% to $20.4 million. EPS climbed 23% to $0.74, while cash increased by $9.0 million to $376.2 million. Artegraft sales surged 34%, and record results were achieved in grafts (+23%), carotid shunts (+18%), and patches (+4%), as well as in EMEA (+18%), APAC (+18%), and the Americas (+5%). Catheter sales declined 11%, but this was offset by strength elsewhere. The company’s guidance for Q3 and Q4 2026 projects continued double-digit revenue and EPS growth, with gross margins expected to remain above 72%. Disclosures are comprehensive for headline metrics, though attributions for margin improvement and product declines are qualitative. Overall, the data supports the company’s claims of accelerating growth and profitability.

Analysis

The announcement's tone is positive but proportionate to the strong, realised financial results disclosed for Q2 2026. Key profitability metrics (operating income, net income, EPS, gross margin) are provided alongside revenue and operational growth, satisfying the disclosure completeness rule for a strong_positive signal. The majority of claims are realised facts, with only a small portion of the release dedicated to forward-looking guidance for the next two quarters and the full year. Capital allocation actions (dividend, share repurchase) are concrete and not framed as transformative. There is no evidence of narrative inflation or exaggerated claims; the language is factual and supported by the data. The only qualitative attributions (e.g., reasons for margin improvement) are minor and do not materially inflate the signal.

Risk flags

• ●The qualitative attribution of gross margin improvement to 'higher prices, mix shift, and operational efficiencies' lacks numerical breakdown, which limits visibility into the sustainability of these drivers.
• ●Catheter sales declined 11% in the quarter, and the explanation of 'recall-driven overstocking in Q2 2025' is not supported by specific data, raising questions about underlying demand trends in that segment.
• ●While six international warehouse expansions are underway, no details are provided on associated costs, timelines, or expected returns, introducing execution and capital allocation risks.

Bottom line

LeMaitre Vascular’s Q2 2026 release shows robust, realised growth across revenue, margins, and earnings, with record results in several product lines and geographies. The company’s capital allocation—dividend and share repurchase—signals confidence in ongoing cash generation. Most claims are substantiated by detailed numbers, though some qualitative explanations lack supporting data. Execution risks exist around international expansion and the underperforming catheter segment, but these are outweighed by broad-based strength elsewhere. For investors, the most important takeaway is that LeMaitre’s growth and profitability are not just projected—they are already materialising, with near-term guidance pointing to continued momentum.

Announcement summary

(NASDAQ: LMAT) LeMaitre Vascular, Inc. reported Q2 2026 sales of $70.4mm, representing a 10% increase (+10% organic) over Q2 2025. Gross margin for the quarter was 72.1%, up 210 basis points, and operating income reached $20.4mm, a 26% increase, with an operating margin of 29%. Earnings per share (EPS) for Q2 2026 was $0.74, up 23% from the prior year, and cash increased $9.0mm sequentially to $376.2mm. Artegraft sales rose 34% in the quarter, with grafts (+23%), carotid shunts (+18%), and patches (+4%) each posting records, as did EMEA (+18%), APAC (+18%), and the Americas (+5%). The company announced a quarterly dividend of $0.25/share, payable on September 3, 2026, to stockholders of record on August 20, 2026, and authorized a share repurchase program of up to $100.0mm. The company projects Q3 2026 sales of $66.3mm - $68.3mm, Q4 2026 sales of $71.1mm - $73.1mm, and full-year 2026 sales of $274.3mm - $278.3mm, with gross margins around 72.2%-72.6% and EPS guidance of $2.84 - $2.94 for the year.

Disagree with this article?